Pediatric CIDP Patients for a Clinical Research Study

Posted on March 18, 2025

Has Your Child been diagnosed with CIDP? Octapharma is seeking Pediatric patients for a clinical research study (NGAM-11) to access two different IVIg doses in the treatment of CIDP

For US Audience Only

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease where the body’s natural defenses, like antibodies, attack the covering of the nerves, called myelin, and damage nerve function. While symptoms aren’t the same for everyone, CIDP can make your arms and legs feel weak and slow your movements. The purpose of the NGAM-11 Study is to evaluate the efficacy of two PANZYGA (IVIG) dose regimens in the treatment of Pediatric CIDP patients. IVIG is commonly used to treat CIDP Patients (Adult and Pediatric) and Octapharma has previously received FDA approval for treatment in adults.

Eligible CIDP patients will be:

Between the ages of 2yrs and 17yrs
Diagnosed with CIDP and have a functional impairment due to CIDP

Expectations during the CIDP study:

Your child will receive a thorough medical exam and the CIDP diagnosis will be confirmed.
If your child qualifies, your child will receive an initial IVIG treatment and then be randomly assigned into one of the two treatment arms where your child will also receive IVIG (active drug) but at different dosage. The infusion is given through a vein in your arm.
The study is 24 weeks in length and your child will be expected to come to the clinic on a monthly basis and receive a total of 6 IVIG infusions. The monthly visits span over 2 days.
Your child will receive study-required medical care throughout the study by a neurologist and the medical team will assess how you are doing.